Περίληψη:
Platelet-activating factor (PAF) is implicated in human immunodeficiency virus (HIV)-related manifestations. Increased PAF synthesis has been recently detected in HIV-infected patients. In this study, we examined in naive HIV-infected patients the in vivo effects of a highly active antiretroviral therapy (HAART) regimen, containing tenofovir-DF/emtricitabine/efavirenz, on PAF metabolism. The specific activities of PAF basic biosynthetic enzymes, PAF-cholinephosphotransferase (PAF-CPT) and lyso-PAF-acetyltransferase (lyso-PAF-AT), but also the ones of PAF-basic catabolic enzymes, PAF acetylhydrolase (PAF-AH) in leukocytes and platelets, and lipoprotein- associated-phospholipase-A2 (LpPLA2) in plasma, were measured in blood samples of eight asymptomatic naive male HIV-infected patients just before and after 1, 3, and 6 months of treatment. CD4 cell counts, viral load, and several biochemical markers were also measured in the same blood samples of these patients. The repeated measures ANOVA and the Pearson r criterion were used to study statistical differences and correlations-partial correlations, while linear mixed models were conducted in order to estimate association(s) between time-dependent changes in these factors. Before treatment, the activities of PAF-CPT in leukocytes and LpPLA2 in plasma were found to be inversely correlated with CD4 cell counts and positively correlated with the viral load. After 6 months of treatment, the activities of basic PAF-biosynthetic enzymes, PAF-CPT and lyso-PAF-AT, were both reduced in leukocytes. At 6 months, PAF-AH activity was also reduced in these cells, while LpPLA2 remained stable. The reduction of PAF-CPT occurred even from the first month, while there is a time-dependent correlation between the increase of CD4 and the decrease of both viral load and PAF-CPT of leukocytes during treatment. Apart from its classical antiretroviral activities the tenofovir-DF/emtricitabine/efavirenz regimen also exhibited favorable effects on PAF metabolism and therefore may also display beneficial effects in some HIV-related conditions, such as cardiovascular disease (CVD), in which PAF is implicated. © Copyright 2012, Mary Ann Liebert, Inc. 2012.
Συγγραφείς:
Chini, M.
Tsoupras, A.B.
Mangafas, N.
Tsogas, N.
Papakonstantinou, V.D.
Fragopoulou, E.
Antonopoulou, S.
Gargalianos, P.
Demopoulos, C.A.
Lazanas, M.C.
Λέξεις-κλειδιά:
acyltransferase; biochemical marker; cholinephosphotransferase; efavirenz plus emtricitabine plus tenofovir disoproxil; phospholipase A2; thrombocyte activating factor, adult; analysis of variance; article; blood sampling; cardiovascular disease; CD4 lymphocyte count; clinical article; correlation coefficient; highly active antiretroviral therapy; human; human cell; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; leukocyte; male; nonhuman; phospholipid metabolism; priority journal; statistical model; virus load, Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; HIV Infections; Humans; Male; Organophosphonates; Oxazines; Platelet Activating Factor; Viral Load
